Go Pro
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.95
-13.3%		$8.39
$1.92
▼
$31.50
$32.82M1.5271,363 shs314,606 shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$0.20
$0.20
$0.18
▼
$1.94
$9.52M1.573.75 million shsN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$0.70
+4.4%		$0.92
$0.51
▼
$1.55
$39.09M1.59738,109 shs124,722 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.73
-1.1%		$4.46
$3.53
▼
$10.48
$37.04M1.1168,948 shs58,897 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
+0.18%-51.11%-74.21%-81.75%-89.46%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
0.00%0.00%0.00%0.00%-89.24%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-3.04%-6.42%-25.53%-31.18%-41.26%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
+3.86%-4.56%-2.58%-49.33%-33.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.95
-13.3%		$8.39
$1.92
▼
$31.50
$32.82M1.5271,363 shs314,606 shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$0.20
$0.20
$0.18
▼
$1.94
$9.52M1.573.75 million shsN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$0.70
+4.4%		$0.92
$0.51
▼
$1.55
$39.09M1.59738,109 shs124,722 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.73
-1.1%		$4.46
$3.53
▼
$10.48
$37.04M1.1168,948 shs58,897 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
+0.18%-51.11%-74.21%-81.75%-89.46%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
0.00%0.00%0.00%0.00%-89.24%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-3.04%-6.42%-25.53%-31.18%-41.26%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
+3.86%-4.56%-2.58%-49.33%-33.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
2.50
Moderate Buy$247.5012,592.31% Upside
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.00
SellN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.33
Hold$9.001,187.55% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
2.00
Hold$24.00543.43% Upside

Current Analyst Ratings Breakdown

Latest EPIX, PDSB, ENLV, and SCYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/21/2026
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/17/2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/10/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/26/2026
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
6/26/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/12/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$122.21 per shareN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.81 per shareN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.18 per shareN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$20.60M1.80N/AN/A$9.07 per share0.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.24B-$8.25N/AN/AN/AN/A248.08%206.39%8/24/2026 (Estimated)
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%N/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$34.50M-$0.67N/AN/AN/AN/A-346.02%-102.36%8/12/2026 (Estimated)
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$8.61M-$3.84N/AN/AN/A-41.79%-57.16%-39.48%8/12/2026 (Estimated)

Latest EPIX, PDSB, ENLV, and SCYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.13N/AN/AN/AN/AN/A
8/12/2026Q2 2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.5067N/AN/AN/A$0.08 millionN/A
5/13/2026Q1 2026
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.15-$0.13+$0.02-$0.13N/AN/A
5/11/2026Q1 2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.10-$0.42-$0.32-$3.36$0.08 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.69839.96%N/AN/A N/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A

Latest EPIX, PDSB, ENLV, and SCYX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/1/2100
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
--$1.698/25/20258/19/20258/22/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
193.24
193.24
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
69.06
69.06
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.73
2.26
2.26
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
3.94
3.94

Institutional Ownership

CompanyInstitutional Ownership
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
26.84%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
8.40%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7016.83 million14.77 millionOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5047.31 million39.98 millionOptionable
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2055.92 million51.23 millionOptionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
609.93 million9.52 millionOptionable

Recent News About These Companies

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319628/0/en/scynexis-initiates-phase-1-study-of-scy-770-a-novel-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd.html
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes
June 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scynexis-shareholders-approve-governance-and-equity-plan-changes?utm_source=marketbeat.com&utm_medium=referral
SCYNEXIS Inc.
June 24, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/Stock/SCYX/financials
SCYNEXIS Announces One-for-Eight Reverse Stock Split
May 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/22/3300360/0/en/scynexis-announces-one-for-eight-reverse-stock-split.html
SCYNEXIS (SCYX) price target increased by 20.73% to 4.28
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/scynexis-scyx-price-target-increased-by-2073-to-428/ar-AA23cbkM
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/11/3292371/0/en/scynexis-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3289542/0/en/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html
SCYNEXIS Raises $40 Million in Strategic Private Placement
April 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCYX/pressreleases/1093176/scynexis-raises-40-million-in-strategic-private-placement/
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript
March 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4887596-scynexis-inc-scyx-discusses-transformative-asset-acquisition-and-strategic-shift-toward-adpkd
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney ...
March 31, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scynexis-completes-transformative-acquisition-of-pxl-770-an-innovative-highly-selective-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-1035979917
Why did SCYX stock jump 10% in pre-market today?
March 31, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/why-did-scyx-stock-jump-10-in-pre-market-today/ar-AA1ZP1Uy
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
March 31, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260331538575/en/poxel-announces-the-sale-of-pxl770-to-scynexis-for-a-total-amount-of-up-to-196-million/
SCYNEXIS Announces $40.0 Million Private Placement
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265281/0/en/scynexis-announces-40-0-million-private-placement.html
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265277/0/en/scynexis-completes-transformative-acquisition-of-pxl-770-an-innovative-highly-selective-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpk.html
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy
March 12, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/scynexis-inc-scyx-announces-first-participants-dosed-in-phase-1-trial-of-scy-247-antifungal-therapy-1714281/
Scynexis: Q4 Earnings Snapshot
March 4, 2026  |  wiltonbulletin.comW
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
March 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/04/3249748/0/en/scynexis-reports-full-year-2025-financial-results-and-provides-corporate-update.html
SCYNEXIS, Inc. Initiates Phase 1 Trial for Intravenous Antifungal SCY-247 Following FDA Designations
February 26, 2026  |  quiverquant.comQ
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
February 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/26/3245564/0/en/scynexis-announces-first-participants-dosed-in-a-phase-1-single-ascending-dose-and-multiple-ascending-dose-trial-of-intravenous-scy-247.html
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
February 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/17/3239199/0/en/cero-therapeutics-announces-biotech-industry-veteran-eric-francois-to-join-its-board-of-directors.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.95 -0.30 (-13.33%)
Closing price 04:00 PM Eastern
Extended Trading
$1.98 +0.03 (+1.28%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$0.70 +0.03 (+4.39%)
Closing price 04:00 PM Eastern
Extended Trading
$0.70 0.00 (-0.43%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$3.73 -0.04 (-1.06%)
Closing price 04:00 PM Eastern
Extended Trading
$3.76 +0.02 (+0.67%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas